- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03453632
Injections of Botulinic Toxin in Plantar Lesions of Localized Epidermolysis Bullosa Simplex (EBTox)
Evaluation of the Efficacy of Injections of Botulinic Toxin in Plantar Lesions of Patients Suffering From Localized Epidermolysis Bullosa Simplex : Double Blind Randomized Controlled Study.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Epidermolysis bullosa is a group of rare genetic diseases characterized by the occurrence of blisters and erosions due to skin fragility. There are 4 different subgroups, based on the location of the skin cleavage area. The most frequent subgroup is the simplex form, consisting predominantly of the localized form (localized epidermolysis bullosa simplex: LEBS). The incidence of LEBS was estimated at between 1/318.000 and 1/35.000. The disease starts early in infancy by the occurrence of blisters and erosions located on soles, secondary to frictions during the walk. The phenomenon is worsened by heat and sudation. LEBS is due to mutations in keratin genes. Life expectancy in LEBS is normal but the quality of life is significantly impaired due to permanent skin pain and limitation of everyday activities (walking, sports). There is no effective or curative treatment. Patients must limit the frictions, protect the skin and use plasters in case of skin lesions.
Botulinic toxin has an agreement for the treatment of axillary hyperhidrosis and has been shown to be also effective on palms and soles. The efficacy of botulinic toxin in plantar lesions of LEBS has been reported in the literature (one case report and a short retrospective series of 6 patients) but there is no proper study.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Contact
- Name: Juliette Mazereeuw-Hautier, MD
- Phone Number: 33 5 67 77 81 41
- Email: mazereeuw-hautier.j@chu-toulouse.fr
Study Contact Backup
- Name: Isabelle DREYFUS, PharmD
- Phone Number: 33 5 67 77 81 10
- Email: dreyfus.i@chu-toulouse.fr
Study Locations
-
-
-
Bordeaux, France, 33000
- Recruiting
- University Hospital Bordeaux
-
Contact:
- Olivier COGREL, MD
-
Nice, France, 06000
- Recruiting
- University Hospital NICE
-
Contact:
- Christine CHIAVERINI, MD
-
Paris, France, 75000
- Recruiting
- Saint-Louis Hospital - APHP
-
Contact:
- Emmanuel Bourrat, MD
-
Toulouse, France, 31059
- Recruiting
- Hôpital Larrey - CHU Toulouse
-
Contact:
- Juliette Mazereeuw-Hautier, Pr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Diagnosis of LEBS based on clinical symptoms and in some cases histological or molecular findings
- Palmar skin lesions: blisters and/or : erosions, edematous and erythematous lesions, crusts. 3 lesions per foot, as a minimum
- Similar clinical severity of skin lesions on both feet
- Patient with social security
- Written consent of the patient
- Patient able to understand the study's questionnaires
Exclusion Criteria:
- Patients with only one leg and a different number of toes on each foot.
- Known hypersensitivity to botulinic toxin or its excipients
- Current treatment with aminosides
- Myasthenia
- Swallowing difficulties
- Respiratory disorders
- Past medical history of dysphagia or pneumopathy of inhalation
- Known allergy or contraindications to lidocaine, prilocaine, paracetamol or nitrous oxide
- Pregnancy (positive pregnancy test (β-HCG) for women of childbearing age, performed within the 2 days prior to the study. Breastfeeding.
- Contraception during 6 months from inclusion
- Mental or physical or judicial incapacity to fill the questionnaires
- Guardianship patients
- Skin infection on the soles at the time of the inclusion
- Skin lesions located on the soles, not related to LEBS (ie. post traumatic wound, wart)
- Patient suffering from dishydrosis
- Botulinic toxin injections in the previous 6 months
- Inclusion in another study in the previous 2 months
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Botulinic toxin
Injections of botulinic toxin (Dysport®, Allergan) 200 UI
|
Clinical photographs of the soles Standardized anesthesia protocol (lidocaine, prilocaine on soles, cryo-spray, oral administration of paracetamol and only if necessary oxycodone and hydroxyzine). Cleaning and antiseptic on the soles Injections of botulinic toxin (200 UI) on right or left foot
Other Names:
|
Placebo Comparator: Placebo
Injections of physiological serum
|
Clinical photographs of the soles Standardized anesthesia protocol (lidocaine, prilocaine on soles, cryo-spray, oral administration of paracetamol and only if necessary oxycodone and hydroxyzine). Cleaning and antiseptic on the soles Injections of physiological serum (200 UI) on right or left foot
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Global clinical improvement on each foot assessed by a blinded centralized independent reviewer using photographs, at M3 vs.baseline: IGA score (Improvement Global Assessment) assessed for each foot
Time Frame: at baseline vs month 3
|
IGA score is a 5-point scale (range from 0 to 4): 0=no improvement or worsening / 1=minimal improvement / 2=moderate improvement / 3=significant improvement / 4=total disappearance
|
at baseline vs month 3
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Global clinical improvement on each foot assessed by a blinded centralized independent reviewer using photographs: IGA score (Improvement Global Assessment) for each foot
Time Frame: at baseline vs month 6
|
IGA score is a 5-point scale (range from 0 to 4): 0=no improvement or worsening / 1=minimal improvement / 2=moderate improvement / 3=significant improvement / 4=total disappearance
|
at baseline vs month 6
|
Global clinical improvement on each foot assessed by the investigator: IGA score (Improvement Global Assessment) assessed for each foot.
Time Frame: at month1, month 3 and month 6 respectively vs baseline
|
IGA score is a 5-point scale (range from 0 to 4): 0=no improvement or worsening / 1=minimal improvement / 2=moderate improvement / 3=significant improvement / 4=total disappearance
|
at month1, month 3 and month 6 respectively vs baseline
|
Efficacy assessment concerning the number of plantar lesions clinically observed by the investigator
Time Frame: at baseline, month 1, month 3 and month 6
|
on each foot (erythematous and edematous areas, blisters, skin erosion, crusts)
|
at baseline, month 1, month 3 and month 6
|
Efficacy assessment on each foot of the affected plantar skin surface (blisters, erosions, erythematous and edematous areas, crusts)
Time Frame: at baseline, month 1, month 3 and month 6
|
calculation of this affected surface by delimiting its contours on a standardized photography using "Image J" software = computerized assessment by a blinded centralized independent reviewer.
|
at baseline, month 1, month 3 and month 6
|
Efficacy assessment by the patient himself, for each foot
Time Frame: at month 1, month 3, month 6 and month 9
|
Global improvement assessed with a 5-point score (0=no improvement or worsening / 1=minimal improvement / 2=moderate improvement / 3=significant improvement / 4=total disappearance)
|
at month 1, month 3, month 6 and month 9
|
Plantar pain assessment by the patient himself, for each foot
Time Frame: at baseline, month 1, month 3 and month 6
|
Plantar pain assessment , using a 0 to 10 pain EVA scale.
To perform the assessment, patient is requested to be standing on one foot (assessment of pain felt for this foot using EVA scale) then, standing on the other foot (assessment of pain felt for this other foot using EVA scale).
|
at baseline, month 1, month 3 and month 6
|
Immediate tolerance during injection :
Time Frame: Day 0
|
Assessment performed by the patient of the pain felt during the act for each foot, using a 0 to 10 pain EVA scale (patient interview).
Assessment performed by the investigator of local adverse events (for each foot) or general adverse events, during the injections
|
Day 0
|
Mid-term and long-term tolerance
Time Frame: Day 0, month 1, month 3 and month 6 and month 9
|
Assessment performed by the patient of local adverse events (for each foot) or general adverse events reported in the home patient's diary between the protocol visits (collected at month 1, month 3, month 6 and month 9).
• Assessment performed by investigator of local adverse events (for each foot) or general adverse events, at D0 (at the end of/after the injections), M3 and M6.
|
Day 0, month 1, month 3 and month 6 and month 9
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Juliette Mazereeuw-Hautier, MD, University Hospital, Toulouse
Publications and helpful links
General Publications
- Fine JD, Bruckner-Tuderman L, Eady RA, Bauer EA, Bauer JW, Has C, Heagerty A, Hintner H, Hovnanian A, Jonkman MF, Leigh I, Marinkovich MP, Martinez AE, McGrath JA, Mellerio JE, Moss C, Murrell DF, Shimizu H, Uitto J, Woodley D, Zambruno G. Inherited epidermolysis bullosa: updated recommendations on diagnosis and classification. J Am Acad Dermatol. 2014 Jun;70(6):1103-26. doi: 10.1016/j.jaad.2014.01.903. Epub 2014 Mar 29.
- Sprecher E. Epidermolysis bullosa simplex. Dermatol Clin. 2010 Jan;28(1):23-32. doi: 10.1016/j.det.2009.10.003.
- Langan SM, Williams HC. A systematic review of randomized controlled trials of treatments for inherited forms of epidermolysis bullosa. Clin Exp Dermatol. 2009 Jan;34(1):20-5. doi: 10.1111/j.1365-2230.2008.02789.x. Epub 2008 Sep 25.
- Abitbol RJ, Zhou LH. Treatment of epidermolysis bullosa simplex, Weber-Cockayne type, with botulinum toxin type A. Arch Dermatol. 2009 Jan;145(1):13-5. doi: 10.1001/archdermatol.2008.546. No abstract available.
- Schwieger-Briel A, Chakkittakandiyil A, Lara-Corrales I, Aujla N, Lane AT, Lucky AW, Bruckner AL, Pope E. Instrument for scoring clinical outcome of research for epidermolysis bullosa: a consensus-generated clinical research tool. Pediatr Dermatol. 2015 Jan-Feb;32(1):41-52. doi: 10.1111/pde.12317. Epub 2014 Mar 20.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Congenital Abnormalities
- Genetic Diseases, Inborn
- Skin Diseases, Genetic
- Skin Diseases, Vesiculobullous
- Skin Abnormalities
- Epidermolysis Bullosa
- Epidermolysis Bullosa Simplex
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Cholinergic Agents
- Membrane Transport Modulators
- Acetylcholine Release Inhibitors
- abobotulinumtoxinA
Other Study ID Numbers
- RC31/16/8917
- 2017-002332-16 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Epidermolysis Bullosa Simplex
-
Castle Creek Pharmaceuticals, LLCCompletedDystrophic Epidermolysis Bullosa | Epidermolysis Bullosa Simplex | Junctional Epidermolysis Bullosa | Epidermolysis Bullosa (EB)United States
-
TWi Biotechnology, Inc.RecruitingGeneralized Epidermolysis Bullosa SimplexUnited States, Taiwan, Australia, Philippines
-
Centre Hospitalier Universitaire de NiceCompletedEpidermolysis Bullosa Simplex Dowling MearaFrance
-
Joyce TengRecruitingHealthy | Epidermolysis Bullosa | Genetic Skin Disease | Epidermolysis Bullosa Dystrophica | Epidermolysis Bullosa Simplex | Epidermolysis Bullosa, JunctionalUnited States
-
ProgenaBiomeRecruitingEpidermolysis Bullosa | Epidermolysis Bullosa Dystrophica | Epidermolysis Bullosa SimplexUnited States
-
InMed Pharmaceuticals Inc.CompletedEpidermolysis Bullosa Dystrophica | Epidermolysis Bullosa Simplex | Epidermolysis Bullosa, Junctional | Kindler SyndromeFrance, Germany, Greece, Israel, Italy
-
Castle Creek Pharmaceuticals, LLCTerminatedEpidermolysis Bullosa SimplexUnited States, Israel, Australia, Austria, France, Germany, Netherlands, United Kingdom
-
Tel-Aviv Sourasky Medical CenterUnknownEpidermolysis Bullosa Simplex
-
Castle Creek Pharmaceuticals, LLCCompletedEpidermolysis Bullosa | Epidermolysis Bullosa SimplexUnited States
-
Centre Hospitalier Universitaire de NiceUnknownEpidermolysis BullosaFrance
Clinical Trials on Botulinic toxin
-
University Hospital, LimogesAllerganCompleted
-
Northwestern UniversityActive, not recruiting
-
Pôle Saint HélierCompleted
-
RenJi HospitalRecruitingInflammatory Bowel Diseases | Microtia | Clostridium Difficile InfectionsChina
-
Swiss Paraplegic Centre NottwilCompleted
-
Queen's UniversityAllerganTerminatedChronic Pain Syndrome | ProstatitisCanada
-
AllerganTerminatedOveractive BladderSerbia, Turkey, Greece, Egypt, Lebanon, India
-
Mentor Worldwide, LLCQuintiles, Inc.CompletedGlabellar RhytidesUnited States
-
Mentor Worldwide, LLCSynteract, Inc.CompletedGlabellar RhytidesUnited States
-
The Hospital of VestfoldSouth-Eastern Norway Regional Health AuthorityCompletedOveractive BladderNorway